# Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

> **NCT05119296** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Stanford University** · enrollment: 12 (actual)

## Conditions studied

- Thyroid Cancer

## Interventions

- **DRUG:** Pembrolizumab (Keytruda)

## Key facts

- **NCT ID:** NCT05119296
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-15
- **Primary completion:** 2025-05-16
- **Final completion:** 2026-09-01
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05119296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05119296, "Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05119296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*